Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 73
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00294736 | A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens | ||
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | ||
| NCT00826449 | Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | ||
| NCT00072618 | Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients | ||
| NCT00385996 | Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | ||
| NCT00072631 | Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer | ||
| NCT00553800 | Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT00123851 | Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | ||
| NCT00642746 | Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) | ||
| NCT01299220 | Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) | ||
| NCT00294762 | Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC | ||
| NCT01334710 | A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer | ||
| NCT00073502 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | ||
| NCT00570232 | UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer | ||
| NCT00042055 | CP-461 for the Treatment of Crohn's Disease | ||
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | ||
| NCT01180959 | Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | ||
| NCT00871923 | Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer | ||
| NCT00036075 | Study Using CP-461 to Treat Advanced Prostate Cancer | ||
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | ||
| NCT00116896 | Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors | ||
| NCT01427205 | Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | ||
| NCT00609804 | Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | ||
| NCT01032070 | Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | ||
| NCT00672243 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | ||
| NCT00036257 | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia | ||
| NCT00603356 | Phase I Study of OSI-930 and Erlotinib in Cancer Tumors | ||
| NCT01567384 | A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies | ||
| NCT01006096 | Erlotinib for Treatment of Psoriasis | ||
| NCT01174043 | Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia | ||
| NCT00570258 | Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy | ||
| NCT01257594 | EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | ||
| NCT00046787 | Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer | ||
| NCT00499655 | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | ||
| NCT00060710 | CP-461 in the Treatment of Patients With Advanced Melanoma | ||
| NCT00088270 | A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer | ||
| NCT00696696 | Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer | ||
| NCT00166426 | Exisulind Versus Placebo After Surgical Removal of the Prostate | ||
| NCT00373425 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors | ||
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00036036 | Study of CP-461 in Patients With Advanced Renal Cell Cancer | ||
| NCT01247922 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | ||
| NCT01154335 | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer | ||
| NCT00380029 | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | ||
| NCT00304278 | Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) | ||
| NCT00254410 | FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | ||
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | ||
| NCT00085839 | Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 | ||
| NCT00283803 | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer | ||
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas |
